➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
Moodys
Express Scripts
Dow
Merck
Baxter

Last Updated: September 27, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR VOXELOTOR

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Voxelotor

Trial ID Title Status Sponsor Phase Start Date Summary
NCT03573882 Study to Assess the Effect of Long-term Treatment With GBT440 in Participants Who Have Completed Treatment in Study GBT440-031 Enrolling by invitation Global Blood Therapeutics Phase 3 2018-06-06 Open Label Extension Study of GBT440 Clinical Trial Patients with Sickle Cell Disease Who Participated in GBT440 Clinical Trials
NCT04000165 Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Escalating Multiple Oral Doses of AG-348 in Subjects With Stable Sickle Cell Disease Recruiting National Heart, Lung, and Blood Institute (NHLBI) Phase 1 2019-07-02 Background: Sickle Cell Disease (SCD) is an inherited blood disorder. People with SCD have abnormal hemoglobin in their red blood cells. Researchers are investigating the safety and efficacy of an investigational medicine called AG-348 (mitapivat sulfate) o determine if it will help people with SCD. Objective: To test the tolerability and safety of AG-348 in people with SCD. Eligibility: People ages 18 and older with SCD. Design: Participants will have 7 visits over approximately 14 weeks. At the first visit participants will be screened with a medical history; a physical exam; and blood, urine, and heart tests. At the following 4 visits participants will stay at the clinic for up to 2 nights. Participants will take study drug in increasing doses for 6 weeks, after which the drug will be tapered off. All visits will include physical exam, blood, and urine tests. The last visit will occur 4 weeks after stopping the drug and also includes a heart test. Participants will provide DNA from the blood samples they provide. The DNA will be tested for an inherited gene that can cause differences in response to the study drug. Researchers may also test other genes to see if they can find any genes that interact with SCD.
NCT04188509 Pediatric Open-Label Extension of Voxelotor Enrolling by invitation Global Blood Therapeutics Phase 3 2019-11-18 Open-label extension study of voxelotor for pediatric participants ages 4 to 18 years old with Sickle Cell Disease who have participated in voxelotor clinical trials.
NCT04218084 Study to Evaluate the Effect of GBT440 on TCD in Pediatrics With Sickle Cell Disease Not yet recruiting Global Blood Therapeutics Phase 3 2020-02-01 This study is a Phase 3, randomized, double-blind, placebo-controlled study of voxelotor in pediatric participants, aged ≥ 2 to < 15 years old, with Sickle Cell Disease. The primary objective is to evaluate the effect of voxelotor on the TCD (Transcranial Doppler Ultrasound) measurements in SCD participants in this age range.
NCT04247594 Dose Escalation Study to Evaluate the Safety, Tolerability, PK and PD of Voxelotor in Patients With SCD Recruiting Global Blood Therapeutics Phase 2 2020-01-09 This is a dose escalation study to evaluate the safety and tolerability of voxelotor at daily doses of 1500 mg to 3000 mg in participants with sickle cell disease (SCD). The study is designed to include 2 separate cohorts. In Cohort A participants will undergo up to 4 periods of voxelotor administration at progressively higher dose levels from 1500 mg until either a maximum tolerated dose (MTD) or 3000 mg orally daily is reached. Cohort B (following Cohort A) will assess the tolerability and safety of doses higher than 1500 mg administered without up-titration.
NCT04335721 A Voxelotor for Sickle Cell Anemia Patients at Highest Risk for Progression of Chronic Kidney Disease Not yet recruiting Global Blood Therapeutics Phase 1/Phase 2 2020-04-01 This study is a single center, prospective exploratory pilot study of Sickle Cell Anemia (SCA) participants. The study will enroll patients with early stages of sickle cell nephropathy (Chronic Kidney Disease (CKD) stage 1 or 2) who are at the highest risk of CKD progression (presence of both hemoglobinuria and urine albumin concentration ≥ 30 mg/g creatinin
NCT04335721 A Voxelotor for Sickle Cell Anemia Patients at Highest Risk for Progression of Chronic Kidney Disease Not yet recruiting University of Illinois at Chicago Phase 1/Phase 2 2020-04-01 This study is a single center, prospective exploratory pilot study of Sickle Cell Anemia (SCA) participants. The study will enroll patients with early stages of sickle cell nephropathy (Chronic Kidney Disease (CKD) stage 1 or 2) who are at the highest risk of CKD progression (presence of both hemoglobinuria and urine albumin concentration ≥ 30 mg/g creatinin
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Voxelotor

Condition Name

Condition Name for Voxelotor
Intervention Trials
Sickle Cell Disease 7
Sickle Cell Anemia 1
Sickle Cell Nephropathy 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Voxelotor
Intervention Trials
Anemia, Sickle Cell 7
Renal Insufficiency, Chronic 1
Kidney Diseases 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Voxelotor

Trials by Country

Trials by Country for Voxelotor
Location Trials
United States 10
United Kingdom 2
Lebanon 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Voxelotor
Location Trials
District of Columbia 1
Maryland 1
Oklahoma 1
New York 1
Tennessee 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Voxelotor

Clinical Trial Phase

Clinical Trial Phase for Voxelotor
Clinical Trial Phase Trials
Phase 4 1
Phase 3 3
Phase 2 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Voxelotor
Clinical Trial Phase Trials
Not yet recruiting 3
Recruiting 2
Enrolling by invitation 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Voxelotor

Sponsor Name

Sponsor Name for Voxelotor
Sponsor Trials
Global Blood Therapeutics 6
University of Illinois at Chicago 1
National Heart, Lung, and Blood Institute (NHLBI) 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Voxelotor
Sponsor Trials
Industry 6
Other 1
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Merck
McKesson
Harvard Business School
Dow
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.